A Clincal Trial of Apatinib Mesylate and Etoposide(VP-16) as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
- 05 Dec 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 04 May 2017 New trial record